Telix Pharmaceuticals Limited
TLX
株式のランク
#4433
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
株価
$10.35
時価総額
$3.52B
変化（1日）
0.03%
変化（1年）
-5.93%
国
AU
取引 Telix Pharmaceuticals Limited (TLX)
カテゴリー
Healthcare
Telix Pharmaceuticals Limited（TLX）のP/E比率
October 2026 時点のP/E比率 TTM 109.12
Telix Pharmaceuticals Limited の最新の財務報告および株価によると、現在の P/E (TTM) は 109.12 です。2023 年末時点での P/E は 617.41 でした。
Telix Pharmaceuticals Limited の P/E 比率の履歴（2000 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 109.12 | -33.18% |
| 2024 | 163.29 | -73.55% |
| 2023 | 617.41 | -2,945.40% |
| 2022 | -21.70 | -20.12% |
| 2021 | -27.17 | 25.39% |
| 2020 | -21.67 | 66.86% |
| 2019 | -12.98 | 36.68% |
| 2018 | -9.50 | -27.18% |
| 2017 | -13.05 | -99.42% |
| 2016 | -2.24K | 360.80% |
| 2015 | -486.09 | 711.45% |
| 2000 | -59.90 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -73.62% |
US
|
|
| -28.36 | -125.99% |
US
|
|
| -24.57 | -122.51% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -72.20% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。